atazanavir capsule
zydus pharmaceuticals usa inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection for patients 3 months and older weighing at least 5 kg. limitations of use: - atazanavir capsules are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus. - use of atazanavir/ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see microbiology (12.4)] . atazanavir is contraindicated: - in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [see warnings and precautions (5.2)] . - when coadministered with drugs that are highly dependent on cyp3a or ugt1a1 for clearance, and for which elevated plasma concentrations of the interacting drugs are asso
atazanavir- atazanavir capsule
camber pharmaceuticals, inc. - atazanavir sulfate (unii: 4mt4vie29p) (atazanavir - unii:qzu4h47a3s) - atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. limitations of use: • atazanavir are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [ see use in specific populations ( 8.4) ]. • use of atazanavir with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [ see microbiology ( 12.4)] . atazanavir capsules are contraindicated: • in patients with previously demonstrated clinically significant hypersensitivity (eg, stevens- johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of atazanavir capsules [ see warnings and precautions (
reyataz capsule
bristol-myers squibb canada - atazanavir (atazanavir sulfate) - capsule - 150mg - atazanavir (atazanavir sulfate) 150mg - hiv protease inhibitors
teva-atazanavir capsule
teva canada limited - atazanavir (atazanavir sulfate) - capsule - 200mg - atazanavir (atazanavir sulfate) 200mg - hiv protease inhibitors
teva-atazanavir capsule
teva canada limited - atazanavir (atazanavir sulfate) - capsule - 300mg - atazanavir (atazanavir sulfate) 300mg - hiv protease inhibitors
apo-atazanavir capsule
apotex inc - atazanavir (atazanavir sulfate) - capsule - 200mg - atazanavir (atazanavir sulfate) 200mg - hiv protease inhibitors
apo-atazanavir capsule
apotex inc - atazanavir (atazanavir sulfate) - capsule - 300mg - atazanavir (atazanavir sulfate) 300mg - hiv protease inhibitors
cipla atazanavir atazanavir 150 mg capsule bottle pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
cipla atazanavir atazanavir 150 mg capsule blister pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).
zanavir ca atazanavir 150 mg capsule bottle pack
cipla australia pty ltd - atazanavir sulfate, quantity: 170.85 mg (equivalent: atazanavir, qty 150 mg) - capsule, hard - excipient ingredients: lactose monohydrate; crospovidone; magnesium stearate; purified water; titanium dioxide; iron oxide red; gelatin; sodium lauryl sulfate - atazanavir is indicated for the treatment of hiv 1 infection, in combination with other antiretroviral agents. this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled studies (see clinical trials).